Stockreport

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

Dare Bioscience, Inc.  (DARE) 
Last dare bioscience, inc. earnings: 8/14 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.darebioscience.com/investor-relations
PDF FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the poten [Read more]